SOLICITATION NOTICE
Q -- GENE TARGETING VECTOR SERVICES WITH OZGENE PTY LTD
- Notice Date
- 8/6/2022 12:48:03 PM
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIAID BETHESDA MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- NOI-NIAID-2135552
- Response Due
- 8/14/2022 1:00:00 PM
- Point of Contact
- DIANA ROHLMAN, Phone: 4063639366, Laura Grey, Phone: 4063759812
- E-Mail Address
-
diana.rohlman@nih.gov, laura.grey@nih.gov
(diana.rohlman@nih.gov, laura.grey@nih.gov)
- Description
- This is a Notice of Intent, not a request for proposal. �The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Ozgene Pty Ltd, located in Bentley, Australia, to procure gene targeting vector services to be used for ongoing experiments under the project code #130315. The OZGENE Service will be used for the generation of customized genetically modified mice for drug validation and medical research trials. The National Institute of Allergy and Infectious Diseases (NIAID) Fungal Pathogenesis Section (FPS) research is broadly focused on characterization of immune response against debilitating fungal infections with an aim to improve patient outcomes via identifying at-risk patient population for early prophylaxis and uncover novel molecules that will aid in development of new immunotherapeutic modalities. The requested supply (genetically modified mouse) Gasdermin D GOF mouse will be used for the exploration of the role of pyroptosis in autoimmune diseases associated with high levels of INF-gamma might further highlight the potential of pyroptosis inhibition as an anti-inflammatory strategy in APECED. Ozgene is a leading company in the generation of customised genetically modified mice for drug validation and medical research trials worldwide, dedicated to providing you with a successful project. Only Ozgene developed the Sequential Cloning System to maximise the efficiency of the cloning process. This has resulted in a reduction in our timeline to construct a targeting vector. In addition, it ensures that all modifications are reliably included and easily confirmed in the final construct. This is as a follow-on to projects and studies previously conducted by Ozgene Pty Ltd in the scope of a larger project.� For ongoing experiments under the project #130315. The OZGENE Service will be used for the generation of customized genetically modified mice for drug validation and medical research trials. The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. �All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-2135552 to Diana Rohlman at diana.rohlman@nih.gov by 4:00 pm eastern standard time August 14, 2022. �All responses received by the closing date of this synopsis will be considered by the Government. �A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. �
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/bec4c24dc7d54521a95cf063b6b63017/view)
- Place of Performance
- Address: Bethesda, MD 20814, USA
- Zip Code: 20814
- Country: USA
- Zip Code: 20814
- Record
- SN06416911-F 20220808/220806230048 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |